4SC to host conference call on 8 November 2012 to present Q3 2012 results
Participants can access the conference call under the following telephone numbers:
Date: 8 November 2012
Time: 3pm CET (9am EST)
+49-6103-485-3000 (other countries)
Approximately two hours after the start of the conference call, an audio replay will be available at 4SC's website www.4sc.com in the section "Investors / Events & Presentations / Conference calls & Webcasts".
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC had 90 employees at 30 June 2012. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.